EP1210583A1 - Procedes in situ de mesure de la liberation d'une substance a partir d'une forme posologique - Google Patents

Procedes in situ de mesure de la liberation d'une substance a partir d'une forme posologique

Info

Publication number
EP1210583A1
EP1210583A1 EP00961420A EP00961420A EP1210583A1 EP 1210583 A1 EP1210583 A1 EP 1210583A1 EP 00961420 A EP00961420 A EP 00961420A EP 00961420 A EP00961420 A EP 00961420A EP 1210583 A1 EP1210583 A1 EP 1210583A1
Authority
EP
European Patent Office
Prior art keywords
ofthe
dissolution
probe
dosage form
vessel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00961420A
Other languages
German (de)
English (en)
Other versions
EP1210583A4 (fr
Inventor
Philip Palermo
Kevin C. Bynum
John Pocreva
Bud Pine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delphian Technology Inc
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of EP1210583A1 publication Critical patent/EP1210583A1/fr
Publication of EP1210583A4 publication Critical patent/EP1210583A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
    • G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
    • G01J3/28—Investigating the spectrum
    • G01J3/42—Absorption spectrometry; Double beam spectrometry; Flicker spectrometry; Reflection spectrometry
    • G01J3/433—Modulation spectrometry; Derivative spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/85—Investigating moving fluids or granular solids
    • G01N21/8507—Probe photometers, i.e. with optical measuring part dipped into fluid sample
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
    • G01N2013/006—Dissolution of tablets or the like
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N2021/6484—Optical fibres
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G01N2021/651—Cuvettes therefore
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/85—Investigating moving fluids or granular solids
    • G01N21/8507—Probe photometers, i.e. with optical measuring part dipped into fluid sample
    • G01N2021/8514—Probe photometers, i.e. with optical measuring part dipped into fluid sample with immersed mirror
    • G01N2021/8521—Probe photometers, i.e. with optical measuring part dipped into fluid sample with immersed mirror with a combination mirror cell-cuvette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/85—Investigating moving fluids or granular solids
    • G01N21/8507—Probe photometers, i.e. with optical measuring part dipped into fluid sample
    • G01N2021/8528—Immerged light conductor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/01—Arrangements or apparatus for facilitating the optical investigation
    • G01N21/03—Cuvette constructions
    • G01N21/05—Flow-through cuvettes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering

Definitions

  • Dissolution testing is required for all solid oral pharmaceutical dosage forms in which absorption ofthe drug is necessary in order for the product to exert the desired therapeutic effect.
  • the U.S. Pharmacopoeia USP is one well-known standard source of information that provides for dissolution and drug release testing in the majority of monographs for such dosage forms. Exceptions are for tablets meeting a requirement for completeness of solution or for rapid (10 to 15 minutes) disintegration of soluble or radiolabled drugs.
  • the apparatus and procedure conform to the requirements and specifications given, e.g., USP 23rd edition Chapter 711 (Dissolution) pages 1791-1793.
  • Dissolution testing serves as a measure of quality control, stability and uniformity as well as a means by which to correlate in- vitro with in-vivo drug release characteristics.
  • a small aliquot of sample is taken from each vessel, usually by a multi channeled pumping system, and transported to either a cuvette or a sample vial for subsequent spectrophotometric or high pressure liquid chromatography (HPLC) analysis, respectively. Plotting percentage dissolution of a solid dosage form through time results in a dissolution profile.
  • HPLC dissolution offers the advantage of specificity, acceptable accuracy, precision and sensitivity, the disadvantage ofthe status quo rather lies with the inherent burden of creating, manipulating, and storing voluminous numbers of sequence and data files.
  • the cost of HPLC, columns, mobile phases, and the waste solvent disposal, etc. is substantial, and the limited number of data points that can be determined may result in a less than an ideal representation ofthe release profile of a solid dosage form over time.
  • HPLC analysis is a sequential time consuming process. In general, a typical 24- hour dissolution requires up to 60 hours in order to generate a dissolution profile.
  • the present invention relates to an improvement in a detection system used for continuously measuring the release of a drug from a pharmaceutical dosage form comprising a singular dissolution vessel or multiple dissolution vessels containing a dissolution medium and a measuring device for detecting the amount of drug released at a given time.
  • Each vessel has a mixing shaft disposed therein for mixing the dissolution medium.
  • the present invention also relates to a method for predicting the dissolution curve provided by a controlled release pharmaceutical dosage form comprising taking continuous measurements ofthe amount of drug released from a dosage form for a portion ofthe time over which the drug is expected to be released and predicting the remainder ofthe dissolution curve based on the values obtained.
  • the present invention relates to in-situ dissolution methods to evaluate and study the dissolution characteristics of drug formulations.
  • Such methods utilize systems that include fiber optics, ultraviolet spectroscopy, fluorescence spectroscopy, NMR and the like.
  • the present invention specifically relates to detection systems for measuring dissolution characteristics of pharmaceutical dosage forms using ultraviolet, IR, near-IR, and Raman spectroscopy techniques as well as electrochemical techniques such as polarography, and NMR.
  • an improved method of analyzing data from an in-situ dissolution system is provided.
  • a sample to be analyzed is placed in a dissolution vessel having a mixing shaft and probe in accordance with the present invention, and a dissolution media is added to the dissolution vessel.
  • Data from the probe is received and an optical spectrum is generated by a spectrometer at selected times during the dissolution ofthe sample in the dissolution media.
  • First a baseline correction (e.g. via a conventional single point baseline correction technique) is applied to the optical spectrum.
  • a portion ofthe spectrum corresponding to the absorption ofthe analyte is then identified, wherein the portion extends from a lower wavelength A, to an upper wavelength B, with an absorbance W at wavelength A, and an absorbance V at wavelength B.
  • the area under the curve (AUC) between wavelength A and B is then calculated.
  • An area of a right triangle (ART) is then calculated, wherein the right triangle has a hypotenuse defined by a straight line extending from point (A, W) to (B, V). Finally, the area ART is subtracted from the area AUC to obtain a measured peak area (MPA).
  • the MPA is proportional to the amount of drug substance in solution.
  • a sample to be analyzed is placed in a dissolution vessel having a mixing shaft and probe in accordance with the present invention, and a dissolution media is added to the dissolution vessel.
  • Data from the probe is received and an optical spectrum is generated by a spectrometer at selected times during the dissolution ofthe sample in the dissolution media as set forth above.
  • a second order derivative is calculated for the optical spectrum in order to correct for scattering interference.
  • a probe which includes an elongated shaft having an opening formed therein, the probe including a light emitting diode and a photodetector disposed on opposing sides ofthe opening.
  • an apparatus for deterrmning a dissolution profile of a pharmaceutical dosage form containing a releasable quantity of a therapeutically active agent which includes a vessel for immersing a pharmaceutical dosage form in a dissolution medium; a probe disposed within the vessel and immersed in the dissolution medium, the probe including a light emitting diode and a photodetector disposed on opposing sides of a flow cell formed in the probe; and a processor coupled to the probe.
  • the flow cell is formed as a bore, aperture, or other opening through the probe.
  • a method for achieving a specified energy level on a spectrometer includes the steps of a) acquiring data from a detector using a first integration time and obtaining a relative energy value as a function thereof; b) comparing the relative energy value with a target relative energy value and, based upon said comparison, either identifying the integration time as an accepted integration time, incrementing the integration time, or decrementing the integration time; and c) repeating steps a and b if the accepted integration time has not been identified.
  • Fig. 1 shows the UV-vis spectra of tramadol standard solutions at four different concentrations
  • Fig. 2 shows the linearity plot of tramadol HCl solutions of Example 1;
  • Fig. 3 is a graphical representation of repeated UV-vis scans at 30-minute intervals over 25 hours for a tramadol HCl 200mg once-a-day tablet of Example 2;
  • Fig. 4 shows a plot ofthe average dissolution of three tramadol HCl once-a-day tablets of Example 2 and the results from the HPLC method;
  • Fig. 5 shows a plot ofthe dissolution of a tramadol tablet of Example 3 over 45 minutes
  • Fig. 6 is a graph ofthe dissolution profile of a tramadol controlled release tablet, using the average dissolution results from table 1, by using TableCurve 2D program, using the best fit equation (as described in Example 4);
  • Fig. 7 is a graph showing the dissolution profile of a tramadol controlled release tablet as described in Example 4 obtained from 12 hour sampling data, at 1 hour intervals, using the best fit equation (as described in Example 4);
  • Fig. 8 is a graph showing the dissolution profile of a tramadol controlled release tablet obtained from 16 hour data, taken at 1 hour intervals, using the best fitted equation (as described in Example 4);
  • Fig. 9 is a graph of a dissolution profile of a tramadol controlled release tablet, when 16 hour data generated at every half hour is used to find the best fit curve (described in Example 4);
  • Fig. 10 shows a plot comparison of dissolution data obtained from both a fiber optics v. HPLC methods (as described in Example 6);
  • Fig. 11 depicts a preferred configuration ofthe present invention
  • Fig. 12 depicts a closed- vessel embodiment ofthe invention
  • Fig. 13 depicts a UV probe in shaft embodiment ofthe invention
  • Fig. 14 illustrates a floating triangle method for determining the area of pre-selected region of a spectrum
  • Fig. 15 illustrates a tangential peak area method for determining the area of a pre-selected region of a spectrum
  • Fig. 16 shows a measured peak area ofthe tangential peak area method of Figure 15;
  • Fig. 17 shows a comparison of a dissolution curve for a 12 mg controlled release hydromorphone capsule measured by the floating triangle method, the tangential peak area method, and an HPLC method;
  • Fig. 18 shows a comparison of a dissolution curve for a 24 mg controlled release hydromorphone capsule measured by the floating triangle method, the tangential peak area method, and an HPLC method;
  • Fig. 19 shows a comparison of a dissolution curve for a 16 mg controlled release hydromorphone capsule measured by the floating triangle method, the tangential peak area method, and an HPLC method;
  • Fig. 20 shows a comparison of a dissolution curve for a 32 mg controlled release hydromorphone capsule measured by the floating triangle method, the tangential peak area method, and an HPLC method;
  • Figs. 21 and 22 illustrate a method for obtaining a second derivative of a spectra in accordance with an embodiment ofthe present invention
  • Fig. 23 shows a comparison of a UV spectra with its first and second derivatives
  • Fig. 24 illustrates the influence of turbidity interference in the analysis of a controlled release tramadol tablet
  • Fig. 25 shows a comparison of a dissolution curve for a 12 mg controlled release hydromorphone capsule measured by a second derivative method, a baseline corrected second derivative method, and an HPLC method;
  • Fig. 26 illustrates the intermediate precision of a 12 mg controlled release hydromorphone capsule by comparing dissolution curves for a capsule generated using the floating triangle method from two different experiments conducted by two different technicians using identical equipment and methods;
  • Fig. 27 illustrates the intermediate precision of a 12 mg controlled release hydromorphone capsule by comparing dissolution curves for a capsule generated using the baseline corrected second derivative method from two different experiments conducted by two different technicians using identical equipment and methods;
  • Fig. 28 illustrates the intermediate precision of a 24 mg controlled release hydromorphone capsule by comparing dissolution curves for a capsule generated using the floating triangle method from two different experiments conducted by two different technicians using identical equipment and methods;
  • Fig. 29 illustrates the intermediate precision of a 24 mg controlled release hydromorphone capsule by comparing dissolution curves for a capsule generated using the baseline corrected second derivative method from two different experiments conducted by two different technicians using identical equipment and methods;
  • Fig. 30 shows a comparison of a dissolution curve for a 12 mg controlled release hydromorphone capsule measured by the floating triangle method, the baseline corrected second derivative method, and an HPLC method;
  • Fig. 31 shows a comparison of a dissolution curve for a 24 mg controlled release hydromorphone capsule measured by the floating triangle method, the baseline corrected second derivative method, and an HPLC method.
  • Figure 32 shows an illustrative fiber optic probe in accordance with a first embodiment of the present invention.
  • Figure 33 shows an illustrative fiber optic probe including the features ofthe second, third, and fourth embodiments ofthe present invention.
  • Figure 34 shows an illustrative fiber optic probe including the features ofthe second, third, and fourth, and fifth embodiments ofthe present invention.
  • Figure 35 shows a non-fiber optic (LED) probe in accordance with another embodiment ofthe present invention.
  • Figure 36 shows an illustrative servo function in accordance with an embodiment ofthe present invention.
  • Figure 37 is a plot of relative energy versus integration time for an illustrative probe as the servo function of Figure 36 is performed.
  • One aspect ofthe present invention is related to an improvement in a detection system for continuously measuring the release of a drug from a pharmaceutical dosage form, the detection system comprising a dissolution vessel containing a dissolution medium and a measuring device for detecting the amount of drug released at a given time, the improvement comprising a mixing shaft having a probe contained within, the probe being capable of measuring the release ofthe drug using fluorescence, ultraviolet (UV), Infrared (IR), near-Infrared (NIR), electrochemical, and Raman spectroscopy techniques.
  • UV ultraviolet
  • IR Infrared
  • NIR near-Infrared
  • the present invention further provides an improvement wherein the probe utilizes ultraviolet spectroscopy techniques, electrochemical techniques, Infrared (IR), near-Infrared (NIR) or Raman spectroscopy techniques.
  • the probe utilizes ultraviolet spectroscopy techniques, electrochemical techniques, Infrared (IR), near-Infrared (NIR) or Raman spectroscopy techniques.
  • Another aspect ofthe present invention provides a method for predicting the dissolution curve provided by a controlled release pharmaceutical dosage form, comprising taking continuous measurements of he amount of drug released from a dosage form for a portion ofthe time over which the drug is expected to be released and predicting the remainder ofthe dissolution curve based on the values obtained.
  • a method according to the present invention utilizes a detection system comprising a singular dissolution vessel or multiple dissolution vessels containing a dissolution medium and a measuring device for detecting the amount of drug released at a given time, the improvement in the detection system comprising a mixing shaft and a probe placed within the mixing shaft or outside the individual dissolution vessels, the probe capable of measuring the dissolution characteristics using UV, IR, near-IR, fluorescence, electrochemical, and Raman spectroscopy techniques.
  • Yet another aspect ofthe present invention relates to an improvement in a detection system for continuously measuring the release of a drug from a pharmaceutical dosage form comprising a plurality of dissolution vessels containing a dissolution medium and a measuring device for detecting the amount of drug released at a given time, the improvement comprising a mixing shaft having a probe contained within, the probe being capable of measuring the release ofthe drug using fluorescence, ultraviolet, Infrared, near-Infrared, elecfrochemical, and Raman spectroscopy techniques. It is further provided that this aspect ofthe present invention may utilize at least two vessels in order to optionally hold a dissolution medium or a placebo formulation for baseline correction.
  • the present invention also provides an improvement in a detection system for continuously measuring the release of a drug from a pharmaceutical dosage form comprising a singular dissolution vessel or multiple dissolution vessels containing a dissolution medium and a measuring device for detecting the amount of drug released at a given time, the improvement comprising a mixing shaft and a probe placed outside the individual dissolution vessels, the probe capable of measuring the dissolution characteristics using UV, IR, near-IR, fluorescence, electrochemical, and Raman spectroscopy techniques. It is further provided that at least two vessels in the inventive system optionally hold a dissolution medium or a placebo formulation for baseline correction.
  • the present invention particularly relates to detection systems for measuring dissolution characteristics of pharmaceutical dosage forms using ultraviolet, IR, near-IR, and Raman spectroscopy techniques as well as electrochemical techmques such as polarography.
  • the present invention also relates to a dissolution apparatus for determining a dissolution profile of a pharmaceutical dosage form containing a releasable quantity of a therapeutically active agent wherein the dosage form is immersed in a dissolution medium contained in a vessel, the apparatus including a detector for quantifying one or more physical and or chemical properties ofthe therapeutically active agent, the detector operatively associated with the dissolution medium for at least the time period required for the dosage form to release the maximum releasable quantity of therapeutically active agent; and a data processor for continually processing the generated data for at least the time period required for the dosage form to release the maximum releasable quantity of therapeutically active agent to obtain a dissolution profile of the dosage form.
  • the present invention also relates to a method for determining a dissolution profile of a pharmaceutical dosage form containing a releasable quantity of a therapeutically active agent wherein the dosage form is immersed in a dissolution medium contained in a vessel, including the steps of continually generating physical and/or chemical data characteristic ofthe therapeutically active agent by operatively associating a detector with the dissolution medium for at least the time period required for the dosage form to release the maximum releasable quantity of therapeutically active agent; and continually processing the generated data with a data processor for at least the time period required for the dosage form to release the maximum releasable quantity of therapeutically active agent to obtain a dissolution profile ofthe dosage form.
  • Another preferred embodiment ofthe invention relates to a dissolution arrangement for measuring in- vitro release of an active agent from a dosage form containing the active agent, including a plurality of vessels, each ofthe vessels containing a dissolution media and a dosage form containing an active agent to be measured, a fiber optic probe associated with each ofthe vessels, each ofthe fiber optic probes including a detector which simultaneously and continuously measures the concentration of active agent in the dissolution media, and a data processor connected to the fiber optic probes, the data processor continually processing information received from the probes concerning the concentration ofthe drug to obtain a dissolution profile of the dosage form.
  • the dissolution arrangement further includes utilizing the data processor to predict future concentrations ofthe active agent.
  • the dissolution arrangement further includes utilizing the data processor to predict the entire dissolution profile ofthe active agent after at least 50 percent ofthe entire desired dissolution time frame has elapsed.
  • the dissolution arrangement further comprises utilizing the data processor to predict a 24-hour dissolution profile ofthe active agent after 16 hours of dissolution time has elapsed.
  • releasable quantity is defined, for purposes ofthe present invention, as the maximum amount of therapeutically active agent that can be released from a pharmaceutical dosage form during the dissolution testing time period. It will be understood by the skilled artisan that the releasable amount may be less than 100% ofthe total amount of agent contained in the pharmaceutical dosage form.
  • the dissolution testing time period is preferably at least one hour, and in certain embodiments is 8-24 hours or longer, e.g., 48, 72 or 96 hours.
  • physical and or chemical properties for purposes ofthe present invention, means physical and/or chemical properties that are characteristic of a particular therapeutically active agent.
  • a non-limiting list of physical and/or chemical properties includes ultraviolet absorption or radiation spectra; infrared abso ⁇ tion or radiation spectra; alpha, beta or gamma radiation; electron states; polarity; magnetic resonance; concentration electro-chemical properties and the like.
  • the physical and/or chemical properties of an agent are any property characteristics of an agent or group of agents that can be used to detect, e.g., the presence, absence, quantity, physical state or chemical state of that agent.
  • agent is defined as any chemical or physical entity or combination of entities, particles or organisms that are detectable by a detector.
  • An exemplary list of agents includes chemicals, therapeutically active agents, radiation particles (e.g., ⁇ -particles); microbes such as bacteria, viruses, individual cells from a multi-cellular organism (e.g., blood cells); and the like.
  • a detector is defined for purposes ofthe present invention as any device that detects a physical and or chemical property of an agent and generates data regarding about the physio- chemical property.
  • detectors are UV-spectrophotometers, Geiger counters, fluoroscopic devices and the like. The physical and or chemical property detected by the detector and the type of data generated by the detector are not critical to the present invention.
  • operatively associated is defined for purposes ofthe present invention as positioning the detector in proximity to the vessel containing the subject agent such that the detector can quantify the desired physical and/or chemical data characteristic ofthe agent, and transmit the data to a data processor.
  • the dissolution apparatus ofthe present invention is particularly useful for determining a dissolution profile of a pharmaceutical dosage form containing a releasable quantity of a therapeutically active agent wherein the dosage form is immersed in a dissolution medium contained in a vessel, the apparatus including a detector for generating physical and/or chemical data characteristic of he therapeutically active agent, said detector operatively associated with the dissolution medium for at least the time period required in order for the dosage form to release the maximum releasable quantity of therapeutically active agent; and a data processor for continually processing the generated data for at least the time period required in order for the dosage form to release the maximum releasable quantity of therapeutically active agent to obtain a dissolution profile ofthe dosage form.
  • the detector may be any detector known in the art that generates physical and/or chemical data ofthe test agent, e.g., a UV spectrophotometer.
  • the detector has a probe communicably attached thereto.
  • there is a corresponding detector capable of continuously generating physical and/or chemical data characteristic ofthe agent to be analyzed.
  • the data processor may be any device capable of continuously processing the data generated by the detector.
  • the data processor is a computer.
  • the data generated by the detector is preferably stored and/or analyzed by the computer.
  • the data collector is a computer that has data processing software, e.g., Microsoft Excel 5.0 or Tablecurve.
  • the data generated by the detector is processed by the software and reorganized into a preferred form, e.g., as a graph or a table.
  • the software preferably continuously processes the data as it is received from the detector.
  • the apparatus further comprises a shaft.
  • the shaft has at least one aperture therein, which aperture allows the detector to detect the necessary physical and or chemical properties ofthe subject agent and generate the required physical and or chemical data.
  • the size and position ofthe opening along the shaft will depend on a variety of factors, including, but not limited to, the type of detector used and the physical and/or chemical property to be detected.
  • the shaft has an orifice therein for receiving the detector.
  • the detector is attached to the shaft.
  • the detector is attached to the shaft by any known attachment means, including, but not limited to, welds, adhesives, soldering, screws, friction, and the like.
  • the detector is permanently attached to the shaft by, for example, soldering the detector to the shaft.
  • the detector is rotatably attached to the shaft in a manner such that, when the detector is received in the shaft, the shaft can freely rotate about the detector, allowing the shaft to perform other functions independent ofthe detector.
  • a paddle or basket may then be affixed to at least one end ofthe shaft such when the shaft is rotated, the paddle or basket also rotates to provide, e.g., agitation when the paddle or basket is contacted with an extemal environment, e.g., dissolution media.
  • the detector measures the concentration ofthe agent, e.g., therapeutically active agent, in the media surrounding the dosage form, e.g., simulated gastric fluid or simulated intestinal fluid.
  • the concentration ofthe agent e.g., therapeutically active agent
  • the detector can be used to measure the amounts of plural agents in the surrounding media.
  • the present invention also relates to a method for determining a dissolution profile of a pharmaceutical dosage form containing a releasable quantity of a therapeutically active agent wherein the dosage form is immersed in a dissolution medium contained in a vessel, including the steps of continually generating physical and or chemical data characteristic ofthe therapeutically active agent by operatively associating a detector with the dissolution medium for at least the time period required for the dosage form to release the maximum releasable quantity of therapeutically active agent; and continually processing the generated data with a data processor for at least the time period required for the dosage form to release the maximum releasable quantity of therapeutically active agent to obtain a dissolution profile ofthe dosage form.
  • the invention includes three components: a conventional dissolution apparatus, a UV detection unit and a Pentium computer running Windows 95 and Excel 5.0 software.
  • the conventional dissolution apparatus a Distek 5100 bathless unit (or equivalent unit), is interfaced to a UV radiation source with fiber optic transmission dip probes, and a series of charge coupled detector (CCD) spectrometers that are internalized in the Pentium computer.
  • the computer is configured with Windows 95 and Excel 5.0 for operation ofthe system and connected to a Novell file server for data storage.
  • Within the Excel software is a template used to run the system.
  • a Dissolution Apparatus is used where vessels are rapidly heated with a thin sheath of electrically resistant material (Distek Premiere 5100 Bathless Unit).
  • a thermocouple present in the shaft of each paddle constantly monitors the temperature of each vessel.
  • the unit uses vessel covers that have been tooled so as to tightly hold fiber optic probes at specified heights.
  • a fiber optic dip probe used for transmission, is interfaced via a sheathed fiber to a deuterium lamp to provide the UV radiation source for the analysis.
  • the dip probe is connected to a CCD spectrometer. Radiation returns from the probe to the CCD spectrometer, where it is analyzed and quantitated.
  • the internal core ofthe fiber consists of fused silica, which allows UV radiation to be efficiently propagated.
  • UV radiation is transmitted from the source lamp through the fiber (which extends into the probe) and through a quartz lens seated directly above the flow cell. UV radiation travels through the flow cell and is reflected off a minor positioned at the terminal end ofthe probe. The radiation then travels back through the flow cell and quartz lens. It is directed into a second fiber where it travels to the spectrometer for analysis. Quantitation ofthe drug substance is accomplished by determining the change in intensity of UV radiation as it is transmitted through the flow cell.
  • the spectrometer itself is comprised of a closed optics bench mounted on a printed circuit board that is situated in the computer system. Upon entering the spectrometer, UV radiation is propagated through an optical slit and onto a grating via a mirror. The radiation is then reflected off a second mirror and onto a charge coupled detector. Each fiber optic probe is interfaced to its own spectrometer using universal SMA fittings.
  • the CCD spectrometer is calibrated for both wavelength accuracy and for quantitative accuracy and precision.
  • a second order polynomial equation is used to determine wavelength accuracy. This equation matches each wavelength of light hitting the CCD with a discrete pixel on the array.
  • the control unit is comprised of a Pentium class computer interfaced to the Novell network and fitted with several CCD spectro- meters, each of which is entirely controlled through a Microsoft Excel 5.0 template consisting of multiple sheets.
  • Excel communicates with the spectrometers via a device driver library.
  • the system parameters can be adjusted by accessing the data acquisition parameters within the Excel worksheet.
  • the parameters for spectrometer control can be set by using either the mouse or keystrokes.
  • the applicable information such as lot numbers and package types are manually entered into the spreadsheet before the test begins.
  • a worksheet presenting real-time data can then be accessed throughout the dissolution. As the data is collected it is stored on the network.
  • the agent is dissolved in the solvent; however, for purposes ofthe present invention, the agent may be dispersed or suspended throughout the solvent in a solid or semi- solid media. Thus, for purposes ofthe present invention, the agent need not be dissolved in the solvent, but may, instead, provide a dispersion or suspension medium for the agent.
  • the device comprises a detector for monitoring chemical and or physical properties of an agent, wherein the detector is mounted to a shaft having a hollow portion capable of receiving said detector, said shaft having an aperture therein that allows said detector to communicate with said external environment when said detector is received by said hollow portion.
  • the detector may be permanently mounted to the shaft, or preferably removably mounted to the shaft to as allow a near infinite combination of shafts and detectors.
  • the mount is preferably a universal mount that will allow an almost infinite combination of detectors and shafts.
  • the detector is capable of acquiring data characteristic of a particular agent by a method selected from the group consisting of ultraviolet radiation, infrared radiation, nuclear magnetic resonance, Raman spectroscopy, electrochemical, and mixtures thereof, with ultraviolet radiation detection being particularly preferred.
  • the shaft is rotatably attached to said detector, such that the shaft is freely rotatable around the peripheral edges ofthe detector when the detector is situated in the hollow portion ofthe shaft.
  • the detector may or may not be attached in a manner to allow the detector to independently rotate about an axis within the hollow portion of the shaft, as desired.
  • the device includes a data collecting means, e.g., a computer.
  • the computer is capable of operating data collection software which facilitates analysis or collection ofthe data generated by the detector.
  • the software may serve to merely store the data, or it may provide comparative analysis to reference standards, produce graphic representations ofthe data (e.g., dissolution vs. time curves), or other assorted functions known in the art.
  • the software will preferably be capable of continuously receiving said data from said detector, providing near- instantaneous access to the data derived from a given test.
  • the detection system further comprises a sampling or dipping manifold for raising and lowering the fiber optic measuring probe to prevent the probe from interfering with the dissolution rate ofthe dosage form.
  • the tip ofthe probe is submerged in the vessel just below the surface ofthe dissolution medium during dissolution and is lowered down into the vessel into USP sampling position immediately before analysis ofthe dissolution rate ofthe dosage form is to take place.
  • the sampling manifold is a motorized manifold that includes an internal motor drive as used in VanKel 7010 Dissolution Test Station (or equivalent). Any other device or method known in the art for raising and lowering a probe within a vessel for testing the dissolution rates ofthe dosage forms are also contemplated to be within the scope ofthe present invention.
  • the present invention is also directed to a method for continuously monitoring an agent in an external environment, e.g., dissolution media, including the steps of collecting data characteristic to a particular agent in an external environment by positioning, at an effective distance to the external environment, a device for continually monitoring the agent in the external environment, said device comprising a detector for detecting an agent in an external environment mounted to a shaft having a hollow portion capable of receiving the detector; the shaft having an aperture that allows the detector to communicate with the external environment; and continuously retrieving data obtained from the detector during the time interval that the device is exposed to the external environment.
  • a device for continually monitoring the agent in the external environment said device comprising a detector for detecting an agent in an external environment mounted to a shaft having a hollow portion capable of receiving the detector; the shaft having an aperture that allows the detector to communicate with the external environment; and continuously retrieving data obtained from the detector during the time interval that the device is exposed to the external environment.
  • the electrochemical techmques used in the present invention optionally include biosensors, in which a transducer is coupled to a biological element, to quantitate a change in concentration of target analyte(s).
  • Examples 1 through 5 illustrate various aspects ofthe in situ system in accordance with the present invention, methods for generating real time dissolution profiles with said in situ system, methods for predicting dissolution profiles with said in situ system, and methods for detection of low dose drugs with said in situ system. They are not to be construed to limit the claims in any manner whatsoever.
  • the in situ dissolution system in accordance with the present invention has been applied to study the dissolution characteristics of pharmaceutical dosage forms, for example analgesic products, such as Tramadol HCl QD Tablets and Hydromo ⁇ hone Capsules.
  • analgesic products such as Tramadol HCl QD Tablets and Hydromo ⁇ hone Capsules.
  • the Ocean Optics Inc. PC Plug-In Fiber Optic Miniature Spectrometer is used with an ultraviolet probe as the method of detection.
  • the probe is coupled to a LS-1 deuterium Ught source and detection is conducted using a SI 000 spectrometer.
  • Data is processed using SpectraScope and Microsoft Excel 5.0 software.
  • the detector is capable of scanning the entire UV and visible spectrum in under 2 seconds. Comparison with the current method for dissolution analysis of solid dosage forms was conducted.
  • a more powerful deuterium light source from Oriel Co ⁇ oration, Stratford, CT can also be used to replace the LS-1 deuterium lamp when higher light throughput is required.
  • This light source also has the advantage of using a condensing lens to manipulate the quality of light hitting the fiber optic interface.
  • a xenon arc lamp source from Oriel Co ⁇ oration may also be used for applications requiring increased sensitivity, such as Hydromo ⁇ hone and Hydrocodone Controlled Release Products.
  • a variable path length dip probe from CIC Photonics, Inc. of Albuquerque NM can be used for method development purposes to determine optimal flow cell path length for a given drug product.
  • Fluorescence studies were conducted on a Perkin Elmer model LS5 Luminescence Spectrometer. The excitation spectrum was obtained from 220 nm to 500 nm and the emission spectrum was taken from 300 to 800 nm.
  • the dissolution bath was a Hansen Research model SR5 with type II (paddle) agitation. The bath temperature was maintained at 37 +/-0.5 degrees and solution was agitated at 100 ⁇ m.
  • Example 1 In-situ system using an Ultraviolet-visible (UV-vis') spectrometer
  • Figure 1 shows the UV-vis spectra of tramadol standard solutions at four different concentrations. Inspection ofthe spectra in Figure 1 reveals relatively noise free data with well- defined spectral features.
  • the absorbance of tramadol vs. concentration at the maximum absorbtivity (272 nm) is shown in Table 1 below.
  • the correlation coefficient ofthe regression line is 0.999825 indicating a linear relationship between concentration and abso ⁇ tion.
  • the linearity plot is shown in Figure 2.
  • Table 1 Linearity of Tramadol HCl
  • a tramadol 200 mg QD tablet was placed in the in-situ dissolution system and the amount of tramadol released monitored in real time. This was obtained by a process called History Channel Evaluation, in which the UV-vis scans ofthe analyte are acquired about every 2.5 seconds. The abso ⁇ tion at a pre-selected wavelength is plotted against time to generate a dissolution profile.
  • Figure 5 displays the plot ofthe dissolution of tramadol tablet over 45 minutes. This example illustrates the feasibility of applying the in-situ system to generate the dissolution profile in real time. This is one ofthe most important applications ofthe proposed system for immediate release products, because FDA is increasingly requiring such information.
  • FIG 11 shows an illustrative system 1 in accordance with an embodiment ofthe present invention.
  • the system 1 includes a computer 20, a display screen 10, a keyboard 40, and a mouse 30.
  • a pluraUty (in this case seven) of CCD's (charge coupled devices) are coupled to the computer 20.
  • the CCD's can be stand-alone external CCD spectrometers (connected to the computer 20 via, for example, a PCMIA card), or can be internal CCD spectrometers comprised of a closed optics bench mounted in card slots of a PCB (printed circuit board) in the computer 20.
  • Examples ofthe internal CCD spectrometers include the PC Plug-In Fiber Optic Miniature Spectrometer manufactured by Ocean Optics, and the HP8452A PDA Spectrophotometer manufactured by Hewlett Packard.
  • each of seven vessels 60 has a fiber optic UV probe 70 and dissolution paddle (not shown) disposed therein.
  • one ofthe vessels 60 will contain the dissolution medium alone, or a placebo formulation in the dissolution medium, in order to provide a baseline spectra (e.g., to be used for a baseline correction calculation).
  • the remaining six vessels 60 can hold the samples to be tested.
  • the system can also be configured with more or fewer than seven vessels.
  • a light source 100 for example an LS-1 Deuterium light source as described above, is coupled to each ofthe fiber optic UV probes 70.
  • Each UV probe 70 extends from the Ught source 100, into the vessel 60, and is coupled at its other end to a respective CCD spectrometer 50.
  • the internal core ofthe fiber consists of fused siUca, which allows UV radiation to be efficiently propagated.
  • Figure 32 shows a first embodiment ofthe fiber optic UV probe 70 having a shaft 101, at the remote end of which (not shown) is connected a light source 100 and a CCD spectrometer 50.
  • Shaft 101 contains a pair of fibers (each preferably comprised of fused silica).
  • probe 70 has a detecting end 103 that contains a lens for focusing light that travels through the fibers.
  • Detecting end 103 while being cylindrically-shaped in this embodiment, can have any suitable shape, so long as it does not interfere with the dissolution being detected.
  • a flow cell 105 is formed as a bore, opening, aperture, or window through end 103. Dissolution medium flows freely through the flow cell 105, such that the dissolution within the medium can be measured.
  • UV radiation is transmitted from the source lamp through a first one ofthe fibers (which extends through shaft 101 into the probe) and through a quartz lens seated directly above the flow cell 105. UV radiation travels through flow cells 105 and is reflected off a mirror positioned at the terminal end ofthe probe on surface 109. The radiation is then directed back through the flow cell 105 and quartz lens into a second one ofthe fibers where it travels through shaft 101 to the spectrometer for analysis. Quantitation ofthe drug substance is accomplished by determining the change in intensity of UV radiation as it is transmitted through the flow cell. As explained above, radiation returns from the fiber optic probe to the CCD spectrometer where it is analyzed and quantitated.
  • UV radiation Upon entering the spectrometer, UV radiation is propagated through an optical sUt and onto a grating via a mirror. The radiation is then reflected off a second mirror and onto a charge coupled detector.
  • Each fiber optic probe is interfaced to its own spectrometer, preferably using universal SMA fittings.
  • the CCD spectrometer is caUbrated for both wavelength accuracy and for quantitative accuracy and precision.
  • a second order polynomial equation is used to determine wavelength accuracy. This equation matches each wavelength of Ught hitting the CCD with a discrete pixel on the array.
  • the system of Figure 11 may utilize open (i.e., uncovered) vessels or, most preferably, may utilize a "closed" (i.e., covered) vessel design as shown in Figure 12.
  • An example of a suitable closed vessel is a Distek 5100 bathless unit. The major advantage of this closed design is to minimize loss of dissolution media.
  • probes 70 are inserted into vessels 60 for measurement of dissolution, and are held approximately midway between the surface ofthe dissolution medium and the bottom ofthe vessels 60.
  • the presence of probes 70 within the medium may interfere with proper dissolution ofthe dosage into the medium, and readings taken by probes 70 that have been situated within vessels 60 may not accurately reflect the true dissolution rates.
  • the USP currently requires that the dissolution medium be sampled approximately midway between the surface ofthe dissolution medium and the bottom ofthe vessels.
  • system 1 may alternatively use a dipping manifold to move the dip probes between a first position just below the surface ofthe dissolution medium and a second position midway between the surface ofthe dissolution medium and the bottom ofthe vessel.
  • the dipping manifold can be controlled to automatically dip the probes 70 into the second position only immediately or a short time period before readings are to be taken (e.g., every 1, 2, 5, or 10 minutes), and then to raise the probes into the first position when readings are not being taken.
  • the dipping manifold can be controlled so as to selectively dip probes 70 into the vessels 60 between the first and second positions (or at any other position relative to the vessel).
  • probes 70 can selectively be dipped into the medium (or raised within the medium) to a point outside the zone of disturbance caused by the agitation ofthe paddles within the medium.
  • An example of a suitable dipping manifold is the manifold in the VanKel 7010 Dissolution Test Station.
  • any other motorized mechanism suitable for moving the dip probes between the first and second positions can alternatively be used.
  • the tip 111 of detecting end 103 of probe 70 is flat and the shaft 101 and detecting end 103 have the same diameter.
  • a potential problem associated with in situ probes is that bubbles may be formed when the probe is inserted into vessel 60. If these bubbles enter the flow cell, they may cause faulty spectral readings, and the resulting measurements may not be accurate. Therefore, in a second embodiment of probe 70, illustrated in Figure 33, the tip 112 of detecting end 103 of probe 70 is conically shaped. The pointed (or conical) tip 112 of probe 70 is intended to reduce the occurrence of bubbles within the fluid when probe 70 is first inserted into the fluid in vessel 60 for measuring the dissolution.
  • shaft 101 has a smaller diameter than detecting end 103 in order to reduce the profile ofthe probe 70 and reduce the hydrodynamic interference generated by the probe in the dissolution media.
  • detecting end 203 of probe 70 has a flow cell 205, bounded by upper surface 207 and lower surface 209, and the opposing ends of detecting end 203 are joined by a single arm 204, which is situated on the side of detecting end 203.
  • This single arm construction is intended to enhance the flow through flow cell 205 and prevent particles from being caught within flow cell 205.
  • the tip 112 of detecting end 203 of probe 70 is conically shaped or pointed (as in the second embodiment described above) and the shaft 101 has a reduced profile (as in the Inird embodiment)
  • the probe in accordance with the third embodiment may alternatively have a flat detecting end 103 and a uniform profile (as in the first embodiment).
  • the second embodiment need not include the features ofthe third and fourth embodiments
  • the third embodiment need not include the features ofthe second and fourth embodiments.
  • Figure 12 shows a vessel 60 with a dissolution paddle 90 disposed therein.
  • the design of such a probe has the advantage of not causing flow aberration, since an additional probe need not be submerged in the dissolution media.
  • Figure 13 shows the dissolution paddle 90 of this embodiment in greater detail.
  • Fiber optic UV probe 70 is shown disposed within the hollow shaft ofthe dissolution paddle 90.
  • a temperature sensor may optionally be disposed within the shaft ofthe paddle.
  • the temperature sensor can be disposed elsewhere within the vessel 60, or eliminated altogether (in which case the temperature setting ofthe heating element could be used as an approximation ofthe temperature ofthe dissolution bath).
  • a window 110 is provided on the shaft in order to allow the dissolution medium to flow through the shaft, thereby providing optical connectivity between the probe and the dissolution medium.
  • a stirring motor 120 is also provided for rotation ofthe dissolution paddle 90.
  • the stirring motor may be controlled via the computer or in any other known manner. In a simple embodiment, the motor simply can be controlled by a switch.
  • the dissolution vessel temperature in the in-situ system can be controlled by a water bath in which vessels are submerged in order to maintain appropriate temperature.
  • the dissolution vessel temperature in the in- situ system can be controlled by a bathless configuration, in which each vessel is surrounded by a heating element. This configuration reduces the size ofthe equipment and consequently the bench space and rninimizes maintenance. It also allows temperature control of each vessel individually and also helps to nrinimize vibration associated with thermocirculation.
  • a heating element appropriate for the bathless configuration is commercially available from Distek, Inc.
  • probes 70 can be situated outside the dissolution vessels 60.
  • near IR that has limited interference from the container, such as glass vessel, is good candidate for use with such a detection probe. This embodiment avoids the issues of turbulence ofthe medium potentially interfering with measurements or the presence ofthe probes 70 within the medium potentially interfering with the dissolution ofthe medium.
  • the present invention can be practiced by detection systems other than those described above.
  • other fiber optic systems can be used, such as (1) Fluorescence, as described in the publication by Glazier, S.A. et al., Analytical Letters (1995) 28, 2607-24, (2) Infrared techniques, as described by Krska, R. et al. in Appl. Phys. Lett. (1993) 63, 1868-70, (3) Near IR and Raman techniques, as described by Cram, D.J. and Hammond, G.S., Organic
  • an electrochemical detection system such as quantitative electrochemical techniques as described by Cooper, J.C. and Hall, E.A., Journal of Biomedical Engineering, (1988) 10, 210-219, including Differential Pulse Voltametry, Current Polarography and Osteryoung Square Wave Voltametry, can be applied to monitor analytes dissolved in dissolution media.
  • electrochemical detection system such as quantitative electrochemical techniques as described by Cooper, J.C. and Hall, E.A., Journal of Biomedical Engineering, (1988) 10, 210-219, including Differential Pulse Voltametry, Current Polarography and Osteryoung Square Wave Voltametry, can be applied to monitor analytes dissolved in dissolution media.
  • These techniques can be used in the in-situ system with different electrode designs, such as platinum or glassy carbon electrodes, for evaluation of different products.
  • a biosensor in which a transducer is coupled to a biological element, can be used to quantitate a change in concentration of target analyte as described by Buerk, D.G. in Biosensors: Theory and Applications, Technomic Publishing, (1993), inco ⁇ orated herein by reference.
  • the biological element can be an enzyme or enzyme system, antigen/antibody, lectin, protein, organelle, cell, or tissue, though enzymes and antigen/antibodies predominate as biological elements of choice, as described by Lowe et al in Journal of Chromatography (1990) 510, 347-354, inco ⁇ orated herein by reference.
  • the biological element is generally immobilized on a support as described by Coulet et al in Journal of Pharmaceutical and Biomedical Engineering (1988) 10, 210-219, inco ⁇ orated herein by reference.
  • the transducer may be optic or fiber optic (measuring most commonly changes in abso ⁇ tion or luminescence), or electrochemical. Superior specificity is one ofthe advantages of biosensors. Such sensors can be used the in-situ system as described herein.
  • a non-fiber optic light source within probe 70 may be used as well.
  • the light is generated by an array of Ught emitting diodes (LEDs) 310 situated at the top 307 of flow cell 305.
  • LEDs Ught emitting diodes
  • a number of LEDs e.g, between 2 and 10
  • a conventional photodiode would be situated at the bottom 309 of flow cell 305 in order to detect the amount of light that passes through the flow cell.
  • a "scan" is then acquired by illuminating the medium within the flow cell 305 with each diode in sequence.
  • probe 70 The only connection from probe 70 is an electrical cable 313, which contains power, data and control wires.
  • detectors may also be used, such as lead sulfide, gallium arsenic (GaAs), gallium (Ga) and indium antimony (InSb).
  • LEDs are available in the LR, UV, and visible regions.
  • the use of LEDs as a light source is appropriate in applications in which the specfroscopic investigation is required only for a limited number of wavelengths, such as quaUty control dissolution testing for a pharmaceutical dosage form.
  • the number of wavelengths which can be used in an LED light source is limited to the number of LEDs which can be housed in the detectors.
  • Another feature ofthe present invention is a servo system for achieving a constant energy level on all spectrometers used in dissolution testing.
  • the servo function acquires reference spectra at varying integration times in order to achieve a given energy level. Longer integration times wiU produce a larger signal.
  • the servo is controlled by a control module, which acquires reference specfra at varying integration times in order to achieve a given energy level.
  • the servo acquires a reference scan at a lowest predetermined integration time.
  • the servo acquires a second reference scan with a new integration time. This procedure is repeated iteratively until an integration time is chosen that produces the desired level of energy, called the Target Percent Relative Energy.
  • the servo assumes that the spectrometer's intensity response is relatively linear over short integration time intervals and that the intensity response is monotonically increasing over the range from the lowest predetermined integration time (e.g., 3.6 ms) to a largest predetermined integration time (e.g. 6,534.7 ms). As set forth below, if these assumptions are not valid for a particular spectrometer, then that spectrometer is considered to be non-functional and an error message is generated.
  • the lowest predetermined integration time e.g., 3.6 ms
  • a largest predetermined integration time e.g. 6,534.7 ms
  • the servo function will be explained in connection with a system in which the lowest predetermined integration time is 3.6 ms (which is the minimum integration time of a Zeiss spectrometer) and 6,534.76 ms (which is the maximum integration time ofthe Zeiss spectrometer).
  • TRE is the Target Relative Energy (percent).
  • MRE Measured Relative Energy (percent).
  • the servo function terminates whenever MRE is within Target Precision units from the Target Percent Relative Energy.
  • the servo calculates a Low Limit (Target Percent Relative Energy - Target Precision) and a High Limit (Target Percent Relative Energy + Target Precision).
  • the servo then terminates at the point that the Measured Relative Energy is greater than or equal to the Low Limit and Measured Relative Energy is less than or equal to the High Limit.
  • the integration time would need to be increased by approximately 40 times (i.e., the ratio of Target Relative Energy to Measured Relative Energy, or 80% / 2%). Accordingly, the calculated new integration time is 144 ms (i.e., 40 times 3.6 ms). Assuming that the spectrometer is perfectly linear, this result provides a measured relative energy of 80% for an integration time of 144 ms, meaning that the servo could terminate its loop after just two steps.
  • step 2 the integration time of 144 ms derived above results in a measured relative energy of 90%.
  • the ratio of TRE to MRE of 0.89 indicates that the integration time needs to be decreased from 144 ms to 128 ms.
  • step 3 the integration time of 128 ms results in a reduced measured relative energy of only 85%, and the resulting ratio of TRE to MRE of 0.94 provides a slightly smaller new integration time of 120.5 ms.
  • step 4 the integration time of 120.5 results in a further relative energy of 81%, which is still slightly outside the desired limits of 80% ⁇ 0.1%.
  • the resulting ratio of TRE to MRE of 0.99 provides a new integration time of 119.0.
  • an integration time of 119.0 ms results in precisely 80% relative energy, and the iterative process is terminated at step 5.
  • the system preferably generates error messages when a spectrometer fails to perform within acceptable limits for the servo system.
  • One indicator of a non-functioning spectrometer is a non-linear intensity response, which occurs when MRE/MRE p ⁇ 0.1 * IT N /IT.
  • the servo system assumes that the spectrometer intensity response is relatively linear such that the increases and/or decreases in relative energy are relatively proportional to the increase and/or decrease in the integration time, from one step to the next.
  • a non-linear intensity response occurs when the proportional relative energy increase/decrease is less than one/tenth that of the integration time increase/decrease.
  • the spectrometer is considered to be non-functional and an error message is generated.
  • a non- functioning spectrometer may be caused by the use of low light intensity, which occurs whenever MRE ⁇ LowLimit and IT > MaxIntegrationTime, i.e., the relative energy is less than the desired LowLimit and the integration time is equal to the maximum integration time. If any of these conditions is detected, a respective error message is generated. In response, the user will investigate the Ught intensity, and, if appropriate, lower (or increase) the Ught intensity to an acceptable level. In addition, if the servo function performs more than a predetermined maximum number of iterations (e.g. 100) without reaching the Target Relative Engery (+/- Target Precision), an error message will be generated.
  • a predetermined maximum number of iterations e.g. 100
  • the data received from each probe is analyzed to determine the percentage of active agent dissolved over time. While this embodiment ofthe invention will be discussed with reference to the system of Figure 11 , other in situ dissolution systems described herein may alternatively be employed.
  • the area of a right triangle is subtracted from the total area under the curve of a relevant spectral region.
  • the area ofthe right triangle which is described in more detail below, closely approximates the remaining scattering contribution.
  • Figure 15 shows how the area under the curve is first defined by the spectral range of analyte (260-296 nm for hydromo ⁇ hone HCl). A baseline subtraction ofthe curve is then applied. The area ofthe baseline-subtracted region is then determined by a trapezoidal approximation (from the Trapezoidal Rule, see Stewart, James, Calculus.2 nd edition 1991, pp.455).
  • the measured peak area (MPA), which is free from scattering interference, is then determined by subtracting the area ofthe right triangle from the total area under the curve, wherein the right triangle is defined by the following points baseline (i), f( ⁇ ), and baseline (ii), and the base ofthe triangle is defined by the baseline(i to ii), as shown in Figure 16.
  • f(x) intersects the baseline at the higher end (point ii) ofthe spectral region.
  • the MPA is proportional to the amount of drug substance in solution.
  • the MPA can be calculated in the following manner. As the calculations are relatively simple, they are particularly well suited for real-time data generation:
  • the baseline measurement is first subtracted from every point in the spectral region (baseline corrected).
  • the Area Under the Curve (AUC) is then calculated using the Trapezoidal Rule, which divides up the area under the curve into frapezoids and then calculates the area ofthe frapezoids.
  • the AUC is then defined as the sum of areas ofthe individual frapezoids. The area of
  • Figure 15 shows this area under the curve as the striped region. This area is not co ⁇ ected for scattering and is not used directly for analytical measurements in this embodiment. In order to correct for scattering, the portion ofthe area that contains the scattering interference must be removed. This is accompUshed by subtracting everything but the analytical "hump" that results from the abso ⁇ tion of our analyte. This can be very closely approximated by removing the area ofthe right triangle, as shown in Figure 16. The area ofthe right triangle (ART) is defined by
  • the measured peak area is defined as the difference ofthe two:
  • Dissolution data was obtained using the HPLC method at 1 hour, 2 hours, 12 hours, 18 hours, and 24 hours, in situ using the floating triangle method (shown in Figure 14) sampling every 10 minutes, and in situ using the tangential peak area method (shown in Figure 15) sampling every 10 minutes.
  • the HPLC data was generated as follows. Dissolution was carried out using USP Apparatus 1 Basket Method ⁇ 711> at 100 RPM. The dissolution media was 900 ml of simulated intestinal fluid without enzymes plus 3 grams sodium chloride per liter at 37° C. The samples used were 12 mg, 24 mg and 32 mg capsules of controlled release hydromo ⁇ hone as described above. The samples were withdrawn at 1 hour, 2 hours, 12 hours, 18 hours and 24 hours and analyzed by HPLC (High Pressure Liquid Chromatography) for hydromo ⁇ hone HCl.
  • HPLC High Pressure Liquid Chromatography
  • the data for the in situ dissolution was generated using the dissolution apparatus of Figure 11, using USP Apparatus 2 Paddle Method at 100 RPM.
  • the dissolution media was 500 ml of simulated intestinal fluid (without enzyme) maintained at 37° C with 3 grams of sodium chloride per liter.
  • the samples used were 12 mg, 24 mg and 32 mg capsules of controlled release hydromo ⁇ hone as described above.
  • the dissolution rated was continuously monitored by a UV Fiber Optic absorbance dip probe, with a 20 mm path length and manufactured by Ocean Optics.
  • the dip probe was placed in the dissolution vessel, adjacent to the mixing shaft as shown in Figure 11.
  • the deuterium light source was manufactured by Oriel Instruments, and the spectrometer was an Ocean Optics PC 1000 Fiber Optic CCD Spectrometer. An absorbance spectrum ofthe dissolution media was generated every 10 minutes for a period of 24 hours.
  • scattering problems associated with in situ dissolution methods are reduced by calculating a second derivative ofthe spectra, subtracting an initial noise offset from the second derivative.
  • the resultant difference value is then proportional to the amount of analyte dissolved.
  • the second derivative ofthe UV specfra ofthe dissolution bath is first calculated.
  • the derivative ofthe spectra at a given point (i) is estimated by determing the slope of a sfraigth line which interconnects a previous specfral data point (i-1) and a next spectral data point (i+1). As shown in Figure 21, this line approximates the derivative at that point because the slope ofthe line between the points (i-1) and (i+1) is nearly the same (parallel) to the tangent line at the specfral data point (i).
  • the derivative at any given point in the spectra can be estimated by calculating the slope between the previous data point and the next data point.
  • Derivative® 284 calculation is carried out for each data point ofthe spectral plot, the derivative ofthe specfra is generated as shown in Figure 23.
  • a second derivative ofthe spectra is taken in order to to co ⁇ ect for scattering. Since the second derivative represents the rate of change ofthe rate of change ofthe function, it will only represent spectral characteristics where a peak is present. Since the scattering interference causes a baseline offset with a variable slope, the second derivative removes this interference. By integrating the area under (and above) the second derivative, using a trapezoidal approximation, a value that is characteristic ofthe amount of analyte in the scattering matrix can be developed.
  • an initial noise offset is subtracted from the plot of the second order derivative ofthe spectral plot.
  • the scattering of a pharmaceutical matrix was simulated by using a photometric standard (turbidity standard) to create an interferance in the spectral observation of a dilute tramadol HCl solution.
  • This experiment was performed using an HP 8452A PDA Specfrophotometer manufactured by Hewlett Packard as the CCD.
  • This Specfrophotometer is a card-type CCD which is mounted within a PCB slot in a computer equipped with a Pentium ® processor.
  • the experiment was conducted by scanning a dilute tramadol standard, and then adding small amounts ofturbidity standard to the sample between scans.
  • the resultant UV specfra shown in Figure 24 are typical for a drug substance in the presence of a scattering matrix (polymer).
  • the amount of analyte was then quantitated using two methods, a standard single point baseline correction, and a 2 nd derivative function in accordance with the present invention.
  • the results are sumarized in the table below .
  • the data in Table 13 demonstrates that the second derivative method in accordance with the present invention provides values that are largely unaffected by how much turbidity standard is added, as is demonsfrated by the very low RSD (relative standard deviation).
  • RSD relative standard deviation
  • a low RSD value i.e., standard deviation/avg. of values
  • the RSD for the baseline subtraction method is significantly greater, indicating that the turbidity ofthe solution has a much greater affect on measured values. This is significant, because it is desirable to accurately quantify the amount of drug dissolved in the dissolution media in a dynamic matrix enviroment, in this case, a sample submerged in a dissolution medium replete with the debris from the partially dissolved sample.
  • HP 8452A PDA specfrophotometer described above includes a built in function that could alternatively be used to calculate the first and second derivative of an acquired spectrum.
  • dissolution data obtained by the HPLC method is compared with dissolution data obtained in situ in accordance with the present invention in Figure 25.
  • the HPLC data is the same data referenced above in connection with Example 6.
  • the in situ data used was generated in the same manner as the data referenced above in connection with Example 6.
  • Figure 25 shows a plot of a second order derivative ofthe in-situ generated spectrum over a period from 0 to 24 hours, sampled every 10 minutes.
  • This initial % dissolved deviation is the result ofthe integration ofthe initial noise ofthe system, which is enhanced significantly by the 2 nd derivative calculation.
  • This corrected 2 nd derivative was then used to recaculate both the accuracy and precision experiments for the 12 mg and 24 mg hydromo ⁇ hone HPLC data set forth above.
  • Figure 26 shows an intermediate precision plot of the 12 mg hydromo ⁇ hone capsule described above.
  • Plots Tl and T2 are both plots ofthe dissolution of the 12 mg capsule described above conducted in situ with the equipment described above.
  • Tl was generated from the same specfral data as the in situ plots of Figure 17.
  • Tl and T2 are derived from data generated by different technicians performing identical measurements on the same apparatus on different days. The data was then processed according to the floating triangle method to produce plots Tl and T2.
  • Figure 27 shows also shows an intermediate precision plot of the 12 mg hydromo ⁇ hone capsule as described above.
  • Plots Tl' and T2' were generated with the 2d derivative baseline corrected method from the identical spectral data as plots Tl and T2, respectively.
  • plots Tl' and T2' were generated from the same data as plots Tl and T2 respectively, the differences between the plots of Figures 26 and 27 are due solely to the different processing methods.
  • a comparison of Figures 26 and 27 clearly demonstrates that the plots generated with the baseline corrected second derivative method are at least as reproducible as the plots ofthe same data with the floating triangle method.
  • Figures 28 and 29 similarly show intermediate precision plots ofthe in situ dissolution of the 24 mg hydromo ⁇ hone capsule described above.
  • the spectral data was generated in the same manner as described above with respect to Example 6.
  • plots T3 and T4 in Figure 28 were derived from data generated by different technicians performing identical measurements on the same apparatus on different days, and the data was processed according to the floating triangle method to produce plots T3 and T4.
  • Plots T3* and T4 1 in Figure 29 were generated with the 2d derivative baseline corrected method from the identical spectral data as plots T3 and T4 of Figure 28, respectively.
  • a comparison of Figures 28 and 29 demonstrates that the plots generated with the baseline corrected second derivative method are at least as reproducible as the plots ofthe same data with the floating triangle method.
  • Figure 30 illustrates a 12 mg accuracy validation which compares HPLC data generated as described in Example 6 with plots Tl (floating triangle method) and Tl' (baseline corrected 2d derivative method).
  • Figure 31 similarly illustrates a 24 mg accuracy validation which compares the HPLC data with plots T3 and T3' in Figures 28 and 29, respectively. Both Figure 30 and Figure 31 demonsfrate that the baseline corrected 2d derivative method more closely correlates to the HPLC data.

Landscapes

  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

L'invention concerne un système de détection utilisé pour mesurer de façon continue la libération d'un médicament d'une forme posologique pharmaceutique, qui comporte un récipient de dissolution ou de multiples récipients de dissolution (60) renfermant un milieu de dissolution, ainsi qu'un dispositif de mesure (50) conçu pour détecter la quantité de médicament libérée à un moment donné.
EP00961420A 1999-08-30 2000-08-30 Procedes in situ de mesure de la liberation d'une substance a partir d'une forme posologique Withdrawn EP1210583A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15144399P 1999-08-30 1999-08-30
US151443P 1999-08-30
PCT/US2000/023800 WO2001016582A1 (fr) 1999-08-30 2000-08-30 Procedes in situ de mesure de la liberation d'une substance a partir d'une forme posologique

Publications (2)

Publication Number Publication Date
EP1210583A1 true EP1210583A1 (fr) 2002-06-05
EP1210583A4 EP1210583A4 (fr) 2004-08-11

Family

ID=22538787

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00961420A Withdrawn EP1210583A4 (fr) 1999-08-30 2000-08-30 Procedes in situ de mesure de la liberation d'une substance a partir d'une forme posologique

Country Status (5)

Country Link
EP (1) EP1210583A4 (fr)
JP (1) JP2003508748A (fr)
AU (1) AU7337500A (fr)
CA (1) CA2383906A1 (fr)
WO (1) WO2001016582A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077616A1 (fr) * 2001-03-27 2002-10-03 Euro-Celtique, S.A. Dispositif a cristal atr
US7620576B1 (en) 2003-01-21 2009-11-17 Trading Technologies International, Inc. Method and apparatus for providing order queue information
US7024955B2 (en) 2003-03-01 2006-04-11 Symyx Technologies, Inc. Methods and systems for dissolution testing
US7809628B1 (en) 2003-05-30 2010-10-05 Trading Technologies International Inc. System and method for estimating order position
JP2005172779A (ja) * 2003-12-10 2005-06-30 Semiconductor Res Found 電磁波を照射してバクテリア、ウィルスおよび毒性物質を測定する方法および装置
GB0524225D0 (en) * 2005-11-29 2006-01-04 Amersham Biosciences Ab Methods and apparatus for detecting and measuring the concentration of a substance in a solution
JP2009063335A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp 生理活性物質と被験物質との相互作用の測定方法
RU2505798C2 (ru) 2008-04-04 2014-01-27 Колгейт-Палмолив Компани Анализ субстратов, на которые нанесены агенты
JP2009075134A (ja) * 2009-01-05 2009-04-09 Junichi Nishizawa 細菌又は毒性物質の同定装置
JP5773914B2 (ja) * 2011-03-11 2015-09-02 ディステック，インコーポレーテッド 中央制御されたモジュール式のモーター式試験
CN102721796A (zh) * 2012-06-27 2012-10-10 浙江省中医药研究院 一种模拟药物局部释药行为的实验装置及其应用
JP6635363B2 (ja) * 2014-10-24 2020-01-22 京都府公立大学法人 腫瘍部位の判別のための方法、腫瘍部位の判別装置
WO2016079797A1 (fr) * 2014-11-18 2016-05-26 日本メクトロン株式会社 Sonde de mesure de concentration en ligne et système de mesure de concentration
CN109975274B (zh) * 2019-04-16 2024-01-23 北京科技大学 一种高炉铁水硅含量在线快速检测装置
US20230384158A1 (en) * 2020-10-26 2023-11-30 Sony Group Corporation Information processing device, information processing method, and program
CN112816446B (zh) * 2020-12-24 2022-02-01 四川长虹电器股份有限公司 一种基于荧光光谱检测荧光轮粉体衰变的方法
CA3223357A1 (fr) * 2021-07-12 2023-01-19 Brigitte Elisa Anna Burm Quantification de substance amelioree dans des melanges complexes
CN117783459B (zh) * 2024-02-28 2024-05-07 沈阳科惠生物医药科技有限公司 一种药物的溶出曲线测定方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070874A (en) * 1990-01-30 1991-12-10 Biocontrol Technology, Inc. Non-invasive determination of glucose concentration in body of patients
WO1997046860A2 (fr) * 1996-06-04 1997-12-11 Euro-Celtique, S.A. Ameliorations apportees a des systemes de detection et a des procedes de prediction de la courbe de dissolution d'un medicament d'une forme galenique pharmaceutique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335438A (en) * 1980-04-17 1982-06-15 Smolen Victor F Method and apparatus for automatic dissolution testing of products
US4740709A (en) * 1986-04-10 1988-04-26 The United States Of America As Represented By The Department Of Health And Human Services Method of sensing fluid properties independent of bubble concentrations
EP0746750B1 (fr) * 1994-02-25 1998-06-03 Distek Inc. Appareil pour mesurer la dissolution
US5679954A (en) * 1994-11-14 1997-10-21 Soloman; Sabrie Non-destructive identification of tablet and tablet dissolution by means of infared spectroscopy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070874A (en) * 1990-01-30 1991-12-10 Biocontrol Technology, Inc. Non-invasive determination of glucose concentration in body of patients
WO1997046860A2 (fr) * 1996-06-04 1997-12-11 Euro-Celtique, S.A. Ameliorations apportees a des systemes de detection et a des procedes de prediction de la courbe de dissolution d'un medicament d'une forme galenique pharmaceutique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANETE F ET AL: "LIQUID-LIQUID EXTRACTION IN CONTINUOUS FLOW SYSTEMS WITHOUT PHASE SEPARATION" ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. COLUMBUS, US, vol. 60, no. 21, 1 November 1988 (1988-11-01), pages 2354-2355, XP000024604 ISSN: 0003-2700 *
See also references of WO0116582A1 *

Also Published As

Publication number Publication date
WO2001016582A1 (fr) 2001-03-08
AU7337500A (en) 2001-03-26
CA2383906A1 (fr) 2001-03-08
JP2003508748A (ja) 2003-03-04
EP1210583A4 (fr) 2004-08-11
WO2001016582A9 (fr) 2002-09-12

Similar Documents

Publication Publication Date Title
US6174497B1 (en) Detection systems and methods for predicting the dissolution curve of a drug from a pharmaceutical dosage form
WO2001016582A1 (fr) Procedes in situ de mesure de la liberation d'une substance a partir d'une forme posologique
US7332128B2 (en) Fiber-optic dissolution systems devices, and methods
Song et al. High-performance fiber-optic pH microsensors for practical physiological measurements using a dual-emission sensitive dye
Kohl et al. The influence of glucose concentration upon the transport of light in tissue-simulating phantoms
Vonach et al. Application of mid-infrared transmission spectrometry to the direct determination of glucose in whole blood
EP2553429B1 (fr) Appareil de mesure portatif, et procédé d'utilisation
Skoulika et al. Rapid quantitative determination of ciprofloxacin in pharmaceuticals by use of solid-state FT-Raman spectroscopy
CA2257106C (fr) Ameliorations apportees a des systemes de detection et a des procedes de prediction de la courbe de dissolution d'un medicament d'une forme galenique pharmaceutique
WO1997046860A9 (fr) Ameliorations apportees a des systemes de detection et a des procedes de prediction de la courbe de dissolution d'un medicament d'une forme galenique pharmaceutique
EP1023583B1 (fr) Methode pour doser des succedanes du sang
Murillo Pulgarín et al. A sensitive resonance Rayleigh scattering sensor for dopamine in urine using upconversion nanoparticles
Heise et al. Investigation of experimental errors in the quantitative analysis of glucose in human blood plasma by ATR-IR spectroscopy
Fanget et al. Correction of inner filter effect in mirror coating cells for trace level fluorescence measurements
WO2003098199A1 (fr) Procedes de mesure in situ de la liberation d'une substance contenue dans une forme dosifiee
Yan et al. Thread-based microfluidic three channel device in combination with thermal lens detection for the determination of copper and zinc
Bijlani et al. Monitoring ibuprofen release from multiparticulates: in situ fiber-optic technique versus the HPLC method: a technical note
Mirza et al. Comprehensive validation scheme for in situ fiber optics dissolution method for pharmaceutical drug product testing
JP3380864B6 (ja) 医薬製剤からの薬物の溶解曲線を予測するための検出系および方法における改良
Dunko et al. Moisture assay of an antifungal by near-infrared diffuse reflectance spectroscopy
CN1271401C (zh) 光纤原位药物溶出度/释放度试验仪
Němcová et al. FIA titrations of phenothiazine derivatives in aqueous micellar and non-aqueous media
Ford et al. Monitoring the heterogeneously catalyzed conversion of quadricyclane to Norbornadiene by Raman spectroscopy
Pedersen et al. A unified method for the determination of gold in biological fluids by flameless atomic absorption spectroscopy
Hu et al. Partial least square analysis of lysozyme near-infrared spectra

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020304

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020304;LT PAYMENT 20020304;LV PAYMENT 20020304;MK PAYMENT 20020304;RO PAYMENT 20020304;SI PAYMENT 20020304

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DELPHIAN TECHNOLOGY INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20040624

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01J 3/433 B

Ipc: 7G 01N 13/00 B

Ipc: 7G 01N 33/15 B

Ipc: 7G 01N 21/63 A

17Q First examination report despatched

Effective date: 20080602

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081213